The COVID-19 pandemic has a major impact on the conduct of most on-going clinical trials, in particular on the treatment of patients and the schedule of their planned protocol visits. General guidance is available from both FDA and EMA on measures to be taken to minimize the impact of COVID-19 on on-going trials; these measures are assumed to have been implemented by Sponsors.
IDDI has published an interview with Marc Buyse, Chief Scientific Officer, and Everardo Saad, Oncologist and Medical Director at IDDI on the impact of the pandemic on the statistical analyses of randomized clinical trials.
Please fill in the form to discover key considerations Marc and Everardo discussed
- PROTOCOL DEVIATIONS AND MISSING DATA
- BEST PRACTICES
- MEDICAL ISSUES AFFECTING TRIAL RESULTS
IDDI’s team is available to answer any question you might have on the impact of COVID-19 on your clinical-trial data, not only from a statistical standpoint but also from a data management standpoint. Do not hesitate to contact us at [email protected] or simply drop a message in our website.